Cabaletta Bio, Inc. 8-K

What Happened
Cabaletta Bio, Inc. (CABA) announced on April 20, 2026 that it posted an updated corporate presentation to the "Investors & Media" section of its website. The company filed a Form 8-K (Item 8.01) disclosing the presentation and attached it as Exhibit 99.1 to the filing. The report was signed by CEO Steven Nichtberger.

Key Details

• Filing date: April 20, 2026 (Form 8-K, Item 8.01).
• Item disclosed: Updated corporate presentation posted to www.cabalettabio.com and furnished as Exhibit 99.1 (dated April 2026).
• No financial results, management changes, or other material events were reported in this filing.
• Report signed by Steven Nichtberger, Chief Executive Officer and President.

Why It Matters
An updated corporate presentation can provide investors with refreshed strategic, clinical, or pipeline information and is a quick way the company shares its latest messaging with the market. This 8-K does not report earnings, executive changes, or new material agreements — it is a disclosure that new investor-facing materials are available on the company website. Investors who want details should review the attached presentation (Exhibit 99.1) on the SEC EDGAR site or the company’s Investor Relations page.